The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients

Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can also trigger immune-related adverse events. Checkpoint inhibitor pneumonitis (CIP) has been reported to have a morbidit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Xiaoyang, Zhang, Jian, Tian, Yaru, Li, Ji, Jing, Wang, Guo, Hongbo, Zhu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476083/
https://www.ncbi.nlm.nih.gov/pubmed/32944393
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476083/
https://www.ncbi.nlm.nih.gov/pubmed/32944393
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0102

Ejemplares similares